Sanofi (Euronext: SAN) has announced that the UK's health technology assessor will conduct a new review of its Sarclisa (isatuximab) combo therapy for relapsed or refractory multiple myeloma.
The review will address treatment at fourth-line in patients whose cancer has advanced after treatment with lenalidomide and a proteasome inhibitor.
The reappraisal follows Sanofi’s successful appeal of an unfavorable draft issued by the National Institute for Health and Care Excellence (NICE) in June, which judged that Isa-Pd would not meet cost-effectiveness criteria even at a hypothetical zero price point.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze